SOURCE: InVivo Therapeutics

InVivo Therapeutics

April 19, 2011 16:11 ET

InVivo Therapeutics to Present at RedChip Virtual Equities Conference April 20, 2011

CAMBRIDGE, MA--(Marketwire - Apr 19, 2011) - InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it will present at the RedChip Small-Cap Equities Virtual Conference VII, to take place April 19-20, 2011.

Frank Reynolds, Chairman & CEO of InVivo Therapeutics, is scheduled to present on Wednesday, April 20, 2011 at 9:30 a.m. EDT. Following the online presentation, investors will have the opportunity to speak one-on-one with Mr. Reynolds during a 15-minute question-and-answer session. The presentation and question-and-answer session will be webcast live at and will be archived for a minimum of 30 days.

RedChip's virtual investor conferences are offered throughout the year and feature publicly traded companies from a wide range of industries including biotechnology, oil & gas, alternative energy, manufacturing, industrial mining, basic materials, business software, construction, internet services, consumer goods, and more. For more information or to register for the RedChip Small-Cap Equities Virtual Conference, please visit

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital in Boston. For more information on InVivo Therapeutics, please visit

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 10-K. We do not undertake to update these forward-looking statements made by us.

Contact Information

  • Contacts:
    Lauren Mitarotondo
    InVivo Therapeutics
    Email Contact